Why Editas Medicine, Inc.’s (EDIT) Stock Is Down 6.45%
As of Monday, November 16, Editas Medicine, Inc.’s EDIT share price has dipped by 6.45%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Tudor Pop
Rosalio Madrigal
Jenna Brashear
Rosalio Madrigal
| Share Statistics | EDIT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $252.3 | $203.5 | 32% |
|
| Shares Out (Mil) | 153.6 | 55.2 | 71% |
|
| Institutional Ownership | 99.7% | 93.3% | 92% |
|
| Float (Mil) | 116.2 | 40.4 | 63% |
|
| Beta | 2.08 | 1.05 | 93% |
|
| Avg Daily Volume (000s) | 2,450 | 569 | 84% |
|
| Price Change (52-week) |
(35.1%) | 38.8% | 29% |
|
| Growth | EDIT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (14.9%) | 13.6% | 4% |
|
| Net Income (5yr) | (6.7%) | (10.7%) | 32% |
|
| EPS (5yr) | 1.8% | 15.4% | 34 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 16.0% | (15.7%) | 74% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.182) | ($0.747) | ($0.727) | |
| Month Ago EPS | ($0.209) | ($0.829) | ($0.753) | |
| # Rev Up | 1 | 0 | 2 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.209) | ($0.829) | ($0.753) | |
| Year/Year Chg | 19.7% | (58.6%) | (64.7%) | |
| Financials | EDIT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $50 | $40 | 20% |
|
| Net Income (TTM) (Mil) | ($72) | ($44) | 13% |
|
| EPS (TTM) | ($0.616) | ($1.400) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($110) | ($35) | 6% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $7 | $4 | 27% |
|
| Enterprise Value (Q1) (Mil) | $210 | $142 | 27% |
|
| Valuation | EDIT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.97 | 1.96 | 71% |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | EDIT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (73.3%) | 67.6% | 2% |
|
| Net Margin | (145.0%) | (50.8%) | 6% |
|
| ROA | (34.3%) | (47.0%) | 15% |
|
| ROE | (147.4%) | (51.8%) | 6% |
|
| Liabilities to Assets | 61.5% | 29.6% | 56% |
|
| F-Score | 4 | 3 | 33% |
|
Editas Medicine, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors